Rezurock (belumosudil) NDC 79802-200

NDC codes

FDA NDC Directory

Product NDC (as listed)79802-200Labeler and product segments. Claims need a package NDC.

Product NDC at billing width79802-0200Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
79802-200-30	79802020030	1 BOTTLE in 1 CARTON (79802-200-30) / 30 TABLET in 1 BOTTLEMarketed from Jul 16, 2021

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rezurock
Generic name (nonproprietary): belumosudil
Active ingredients: Belumosudil — 200 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Kadmon Pharmaceuticals, LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 214783
Marketing start: Jul 16, 2021
Listing expires: Dec 31, 2027
Identifiers: Product ID 79802-200_65249371-3fc5-4a85-a999-9ed367b8dd73SPL ID 65249371-3fc5-4a85-a999-9ed367b8dd73SPL set ID 102e4ef4-7f84-4e34-8df1-479c24d1575dRxCUI 2564031, 2564037UNII 834YJF89WO

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N479802020030 followed by a unit qualifier and the quantity

Package 79802-0200-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 7, 2026.

Indications (excerpt from the label)

REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. REZUROCK is a kinase inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)